Profile Lead Compounds in Own Lab

Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a flexible and complete kinase solution for the profiling of lead compounds against kinases representative of all major families of the kinome. Through using this single platform, scientists can easily profile lead compounds in their own laboratories in a cost-effective manner with no loss in sensitivity.

The complete solution is accomplished by combining an expanding series of unique Kinase Enzyme Systems with Promega ADP-Glo™ Kinase Assay. The Kinase Enzyme Systems, used in concert with the new universal, bioluminescent ADP-Glo Kinase Assay from Promega, provide all of the necessary tools and give drug screeners unprecedented ease to profile inhibitors against the human kinome for off-target effects.

Each Kinase System is composed of a unique protein kinase enzyme, cognate kinase substrate and enzyme buffer. All of the Kinase Enzyme Systems have been optimized and QC'd with the ADP-Glo Assay. The ADP-Glo Kinase Assay is as sensitive as radiometric kinase assays and is quickly replacing such traditional technology.

"This partnering of SignalChem's kinase reagents with the Promega ADP-Glo detection assay for kinases is an ideal fit. Now researchers can obtain all the necessary components to test protein kinase inhibition from a single source while still obtaining the level of sensitivity obtained with traditional radiometric assays." said Jasbinder Sanghera, Ph.D., President & CSO of SignalChem Pharmaceuticals, of British Columbia, Canada.

Promega is the sole distributor of Kinase Enzymes Systems from SignalChem. Each Kinase Enzyme System will be available as a stand-alone enzyme system or will be sold together with ADP-Glo Assay.